Literature DB >> 33525443

Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis.

Gian Paolo Caviglia1, Angelo Armandi1, Chiara Rosso1, Davide Giuseppe Ribaldone1, Rinaldo Pellicano2, Sharmila Fagoonee3.   

Abstract

Hepatitis B virus (HBV) covalently-closed-circular (ccc)DNA is the key molecule responsible for viral persistence within infected hepatocytes. The evaluation of HBV cccDNA is crucial for the management of patients with chronic HBV infection and for the personalization of treatment. However, the need for liver biopsy is the principal obstacle for the assessment of intrahepatic HBV cccDNA. In the last decade, several studies have investigated the performance of hepatitis B core-related antigen (HBcrAg) as a surrogate of HBV cccDNA amount in the liver. In this meta-analysis, we collected 14 studies (1271 patients) investigating the correlation between serum HBcrAg and intrahepatic HBV cccDNA. Serum HBcrAg showed a high correlation with intrahepatic HBV cccDNA (r = 0.641, 95% confidence interval (CI) 0.510-0.743, p < 0.001). In a head-to-head comparison, we observed that the performance of HBcrAg was significantly superior to that of hepatitis B surface antigen (r = 0.665 vs. r = 0.475, respectively, p < 0.001). Subgroup analysis showed that the correlation between HBcrAg and intrahepatic HBV cccDNA was high, both in hepatitis B e antigen-positive and -negative patients (r = 0.678, 95% CI 0.403-0.840, p < 0.001, and r = 0.578, 95% CI 0.344-0.744, p < 0.001, respectively). In conclusion, the measurement of serum HBcrAg qualifies as a reliable non-invasive surrogate for the assessment of an intrahepatic HBV cccDNA reservoir.

Entities:  

Keywords:  HBV cccDNA; HBcrAg; HBeAg; HBsAg; chronic HBV infection

Year:  2021        PMID: 33525443      PMCID: PMC7910971          DOI: 10.3390/diagnostics11020187

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  52 in total

1.  Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.

Authors:  Maurizia R Brunetto; Patrick Marcellin; Beatrice Cherubini; Cihan Yurdaydin; Patrizia Farci; Stephanos J Hadziyannis; Vivien Rothe; Loredana Regep; Ferruccio Bonino
Journal:  J Hepatol       Date:  2013-07-18       Impact factor: 25.083

2.  Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain.

Authors:  Tatsuji Kimura; Nobuhiko Ohno; Nobuo Terada; Akinori Rokuhara; Akihiro Matsumoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Shinichi Ohno; Noboru Maki
Journal:  J Biol Chem       Date:  2005-04-04       Impact factor: 5.157

Review 3.  Non-invasive biomarkers for chronic hepatitis B virus infection management.

Authors:  Caroline Charre; Massimo Levrero; Fabien Zoulim; Caroline Scholtès
Journal:  Antiviral Res       Date:  2019-07-06       Impact factor: 5.970

4.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

Review 5.  Chronic hepatitis B therapy: available drugs and treatment guidelines.

Authors:  G P Caviglia; M L Abate; R Pellicano; A Smedile
Journal:  Minerva Gastroenterol Dietol       Date:  2014-10-17

6.  Proposed model for the prediction of intrahepatic covalently closed circular DNA level in patients with chronic hepatitis B.

Authors:  Kunihiro Hasegawa; Hiroki Nishikawa; Hirayuki Enomoto; Yoshinori Iwata; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kazunori Yoh; Noriko Ishii; Yukihisa Yuri; Takashi Nishimura; Hiroko Iijima; Etsuro Hatano; Jiro Fujimoto; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2018-11-26       Impact factor: 4.288

7.  Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection.

Authors:  Danny Ka-Ho Wong; Yasuhito Tanaka; Ching-Lung Lai; Masashi Mizokami; James Fung; Man-Fung Yuen
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

8.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

Review 9.  Chronic hepatitis B virus infection.

Authors:  Wai-Kay Seto; Ying-Ru Lo; Jean-Michel Pawlotsky; Man-Fung Yuen
Journal:  Lancet       Date:  2018-11-24       Impact factor: 79.321

10.  Moving towards core antigen for the management of patients with overt and occult HBV infection.

Authors:  Angelo Armandi; Chiara Rosso; Davide G Ribaldone; Gian P Caviglia
Journal:  Panminerva Med       Date:  2020-10-19       Impact factor: 5.197

View more
  4 in total

1.  A Novel Trademark Image Retrieval System Based on Multi-Feature Extraction and Deep Networks.

Authors:  Sandra Jardim; João António; Carlos Mora; Artur Almeida
Journal:  J Imaging       Date:  2022-09-02

Review 2.  Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management.

Authors:  Alicia Vachon; Carla Osiowy
Journal:  Viruses       Date:  2021-05-21       Impact factor: 5.048

3.  Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients.

Authors:  Han Ah Lee; Hyun Woong Lee; Younhee Park; Hyon-Suk Kim; Yeon Seok Seo
Journal:  J Clin Med       Date:  2022-03-21       Impact factor: 4.241

Review 4.  Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update.

Authors:  James Lok; Kosh Agarwal
Journal:  Viruses       Date:  2021-07-10       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.